Effects of UFT on Thymidylate Synthase and Dihydropyrimidine Dehydrogenase Activities in Lung Cancer

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4153-4156

  Miyamoto, Hideaki ^a   Morio, Atsuo ^a   Izumi, Hiroshi ^a   Yamazaki, Akio ^a   Wang, Zumin ^a   Futagawa, Toshiroh ^a   Sonobe, Satoshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Non small cell lung cancer; Thymidylate synthase; Thymidylate synthase inhibition rate; UFT

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; UFT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG; LUNG NON SMALL CELL CANCER; LYMPH NODE; LYMPH NODE METASTASIS; PRIORITY JOURNAL; SIDE EFFECT; TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; TEGAFUR; THYMIDYLATE SYNTHASE; URACIL;

EID: 0344009657     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Hirata K, Sasaki K, Yamamitsu S et al: A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus UFT in plasma of same patient. Jpn J Cancer Res 20: 1409-1411, 1993.
2. Ikenaka K, Shirasaka T, Kitano S and Fujii S: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70: 353-359, 1979.
3. 1-(2'tertahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085-2088, 1998.
4. Morio A, Miyamoto H, Izumi H et al: Drug concentration in lymph nodes after preoperative administration of UFT (a blend of tegafur and uracil) for non-small cell lung cancer. Int J Clin Oncol 5: 247-252, 2000.
5. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology 13(suppl. 3): 17-21, 1999.
6. Johnston PG, Fisher ER et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
7. Lenz HJ, Leichman CG et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996.
8. Huang CL, Yokomise H, Kobayashi S et al: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
9. Spears CP, Shahinian AH, Moran RG et al: In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982.
10. Takechi T, Uchida J, Fujioka A et al: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11: 1041-1044, 1997.